目的 探討元胡止痛滴丸聯(lián)合苯甲酸利扎曲普坦片治療偏頭痛的臨床療效。方法 納入2022年1月—2023年12月在新鄉(xiāng)醫(yī)學(xué)院第一附屬醫(yī)院就診的160偏頭痛患者，按照隨機(jī)數(shù)字表法分為對照組和治療組，每組各80例。對照組患者口服苯甲酸利扎曲普坦片，10 mg/次，2次/d；治療組在對照組基礎(chǔ)上口服元胡止痛滴丸，20丸/次，3次/d。兩組患者均治療1個(gè)月。觀察兩組患者臨床療效，比較治療前后兩組患者VAS評分和VAS評分降低至少50%所需時(shí)間，及血漿黏度（PV）、全血低切黏度（LSWBV）、全血高切黏度（HSWBV）、纖維蛋白原（FIB）、5-羥色胺（5-HT）、一氧化氮（NO）、多巴胺（DA）、降鈣素基因相關(guān)肽（CGRP）、白細(xì)胞介素-1β（IL-1β）和腫瘤壞死因子-α（TNF-α）水平。結(jié)果 治療后，對照組總有效率為78.75%，治療組總有效率為91.25%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組VAS評分均顯著降低（P＜0.05），且治療組VAS評分顯著低于對照組（P＜0.05）。治療后，治療組VAS評分降低至少50%所需時(shí)間顯著低于對照組（P＜0.05）。治療后，兩組PV、LSWBV、HSWBV、FIB、NO、CGRP、DA、IL-1β和TNF-α水平均顯著降低，而5-HT水平均顯著升高（P＜0.05），且治療組這些指標(biāo)水平均顯著好于對照組（P＜0.05）。結(jié)論 元胡止痛滴丸聯(lián)合利扎曲普坦治療偏頭痛臨床療效顯著，且安全性高，能快速緩解患者頭痛癥狀，可能與改善血液黏度、神經(jīng)遞質(zhì)及炎癥因子的表達(dá)水平等有關(guān)。

Objective To investigate the clinical efficacy of Yuanhu Zhitong Pills combined with rizatriptan in treatment of migraine. Methods Patients (160 cases) with migraine in the First Affiliated Hospital of Xinxiang Medical University from January 2022 to December 2023 were divided into control and treatment group according to the random number table method, and each group had 80 cases. Patients in the control group were po administered with Rizatriptan Monobenzoate Tablets, 10 mg/time, twice daily. Patients in the treatment group were po administered with Yuanhu Zhitong Pills on the basis of the control group, 20 pills/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical evaluations were evaluated, the VAS scores and the time of VAS score decreased more than 50%, and the levels of PV, LSWBV, HSWBV, FIB, 5-HT, NO, CGRP, DA, IL-1β, and TNF-α in two groups before and after treatment were compared. Results After treatment, the total effective rate in the control group was 78.75%, the total effective rate in the treatment group was 91.25%, and the difference between the two groups was statistically significant (P < 0.05). After treatment, VAS scores in two groups were significantly reduced (P < 0.05), and VAS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the time required for the VAS score to decrease by at least 50% in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the levels of PV, LSWBV, HSWBV, FIB, NO, CGRP, DA, IL-1β, and TNF-α were significantly decreased in two groups, while the levels of 5-HT were significantly increased (P < 0.05), and the levels of these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Yuanhu Zhitong Pills combined with rizatriptan benzoate have significant clinical efficacy and high safety in the treatment of migraine. It can quickly relieve headache symptoms in patients, which may be related to improving blood viscosity, expression levels of neurotransmitters and inflammatory factors.

R971

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20200488）